Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment, and followed by Grand Mount Capital and Seeking Capital (an existing investor). After this round of financing, Zhiyin Lan, venture partner of LH Ventures, will join the Board of Directors of Sanyou Bio. Previously, Sanyou Bio obtained joint series-A funding from Haier Biomedical and Shanghai Liferiver Bio-Tech in May 2020.
Sanyou Bio Expert in innovative therapeutic antibody R&D
Established in 2015, Sanyou Bio focuses on R&D of innovative antibody drugs. The Company's vision is to improve quality of life with innovative antibody drugs, and their mission is to empower the industry to develop any innovative antibody drug. Sanyou Bio have been continuously building a world-leading high-throughput integrated R&D platform for innovative antibody drugs, collecting technical resources to establish the largest antibody library in the world. While providing leading services, Sanyou Bio have made every effort to collaborate with their partners to develop innovative antibody drugs to meet the patients' need.
After 6 years of persistent endeavor, Sanyou Bio has established a state-of-the-art integrated R&D platform for innovative antibody drug discovery, provided hundreds of unique R&D solutions and technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug development institutions around the world, and carried out more than 10 collaborative R&D projects with more than 10 partners.
Dr. David (Guojun) Lang, CEO of Sanyou Bio, stated, "we are very grateful to our previous and new investors for their recognition and support. We will make the best use of this funding round to expand our R&D and service teams, expedite the launching process of a number of super-trillion antibody libraries, and build a world-leading modular, automated, and integrated innovative antibody drug integrated R&D service platform to overcome the difficulty of finding top-notch candidate molecules of innovative antibody drugs and clear the path from a target selection to IND application. We hope that all companies and individuals aspired to R&D of innovative antibody drugs can leverage fully with Sanyou Bio's open platform to achieve their pursuit of new drug development."
Investors' messages
Zhiyin Lan, venture partner of LH Ventures, stated, "LH Ventures commits to long-term value investment, actively promotes the innovation and growth of Chinese enterprises, and promotes industrial progresses and development. Sanyou Bio has devoted in antibody drug discovery for years, and established a comprehensive integrated R&D platform and equipped with leading competence in innovative antibody drug discovery. We are very excited to join this round of investment to assist Sanyou Bio in building a world-leading R&D service platform for innovative antibody drugs."
Yinghua Zeng, chief investment officer of Montesy Investment stated, " Montesy has focused on forefront progresses in the area of innovative antibody drugs for a long time. Sanyou Bio focuses on R&D services of innovative antibody drugs and implements dual business patterns of services plus collaborative R&D. We highly recognize the technical competence and execution efficiency of Sanyou Bio's team. We believe that Sanyou Bio can assist Chinese pharmaceutical industry and promote drug development in China."
Shanshan Zhang, president of Grand Mount Capital, stated, "Innovative antibody drugs are one of the fastest growing sectors in biopharmaceutical industry, and have long-term investment values. Sanyou Bio has devoted in innovative antibody drug R&D and services for years, has world-leading technical competence in integrated antibody drug R&D, and has been continuously strengthening the construction of its own R&D platform. We highly recognize the dedication and execution capability of Sanyou Bio's management team. As one of the investors of this funding round, we will assist Sanyou Bio for its continuous breakthrough to reach more milestones. We believe that ...










(All Rights Reserved)